| Name | Title | Contact Details |
|---|
Founded in 2013, Organigram is a leading Canadian licensed producer, focused on producing high-quality, indoor-grown cannabis for adult recreational consumers in all provinces and the Yukon. Headquartered in Toronto, Organigram has three state-of-the-art cultivation and processing facilities in Moncton, Winnipeg and Lac-Supérieur, and its adult-use products can be found in retail outlets from coast-to-coast. Organigram`s adult-use brands include Edison, SHRED, monjour, Laurentian Cannabis, Holy Mountain, Big Bag O`Buds, Tremblant Cannabis and Trailblazer.
Karuna Pharmaceuticals is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.
Were reimagining how technology can solve #stroke`s unmet needs, enabling providers with the ability to raise the standard of care for patients.
MIND 24-7 is fundamentally changing the landscape of accessible behavioral health by offering walk-in urgent mental health and substance abuse services such as Psych Express Care, Psych Crisis Care, and Psych Progressions. MIND 24-7 fills the gap for those seeking help by being available right when they need it – 24 hours a day, 365 days a year. Using innovations in value-based care models to improve and expand access to care, MIND 24-7 not only enhances quality patient care, but reduces pressure on the system, reducing costly emergency room visits, in-patient treatment, and readmissions for crisis care.
Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.